CA3149270A1 - Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof - Google Patents

Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof Download PDF

Info

Publication number
CA3149270A1
CA3149270A1 CA3149270A CA3149270A CA3149270A1 CA 3149270 A1 CA3149270 A1 CA 3149270A1 CA 3149270 A CA3149270 A CA 3149270A CA 3149270 A CA3149270 A CA 3149270A CA 3149270 A1 CA3149270 A1 CA 3149270A1
Authority
CA
Canada
Prior art keywords
amount
cyclosporine
castor oil
ophthalmic composition
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3149270A
Other languages
English (en)
French (fr)
Inventor
Joon Youb Lee
Youn Jae Shin
Hyun Won Seo
Dae Hun Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taejoon Pharmaceutical Co Ltd
Original Assignee
Taejoon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taejoon Pharmaceutical Co Ltd filed Critical Taejoon Pharmaceutical Co Ltd
Publication of CA3149270A1 publication Critical patent/CA3149270A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3149270A 2019-09-09 2020-09-04 Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof Pending CA3149270A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190111776 2019-09-09
KR10-2019-0111776 2019-09-09
PCT/KR2020/011977 WO2021049825A1 (ko) 2019-09-09 2020-09-04 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법

Publications (1)

Publication Number Publication Date
CA3149270A1 true CA3149270A1 (en) 2021-03-18

Family

ID=74867274

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3149270A Pending CA3149270A1 (en) 2019-09-09 2020-09-04 Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof

Country Status (8)

Country Link
US (1) US12576126B2 (OSRAM)
EP (1) EP4029493A4 (OSRAM)
JP (1) JP2022548221A (OSRAM)
KR (2) KR102273481B1 (OSRAM)
CN (1) CN114364372A (OSRAM)
CA (1) CA3149270A1 (OSRAM)
PH (1) PH12022550500A1 (OSRAM)
WO (1) WO2021049825A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023190283A1 (ja) * 2022-03-28 2023-10-05 中外製薬株式会社 ポリオキシエチレン構造を含む油性成分を含有する化合物製剤
IL294896A (en) * 2022-07-20 2024-02-01 LYOTROPIC DELIVERY SYSTEMS Ltd Topical administration of cyclosporine to the eye

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635796B2 (en) 1990-03-16 2003-10-21 Sevenson Environmental Services, Inc. Reduction of leachability and solubility of radionuclides and radioactive substances in contaminated soils and materials
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US8663692B1 (en) 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
CN101448259A (zh) 2001-06-27 2009-06-03 诺基亚西门子通信公司 用于无线通信网中承载授权的方法和系统
WO2003053472A1 (en) 2001-12-21 2003-07-03 Senju Pharmaceutical Co., Ltd. Eye drops
MXPA04009385A (es) 2002-03-26 2005-01-25 Teva Pharma Microparticulas de drogas.
CN1232539C (zh) * 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
JP2006524190A (ja) * 2003-02-20 2006-10-26 テバ ファーマシューティカル インダストリーズ リミティド 薬剤のメントール溶液
US20070008894A1 (en) 2004-10-19 2007-01-11 Idt Corporation Telecommunications-based link monitoring system
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
KR100669510B1 (ko) 2005-08-17 2007-01-16 보람제약주식회사 사이크로스포린을 함유한 나노 에멀젼 농축액 조성물 및 그제조방법
CN101244256A (zh) * 2007-02-16 2008-08-20 中国科学院上海药物研究所 一种环孢菌素a眼用微/亚微乳原位凝胶制剂及其制备方法
EP2575854B1 (en) * 2010-05-25 2016-03-09 Allergan, Inc. Cyclosporin emulsions
WO2012015211A2 (ko) 2010-07-30 2012-02-02 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
US8455991B2 (en) 2010-09-24 2013-06-04 Stats Chippac Ltd. Integrated circuit packaging system with warpage control and method of manufacture thereof
US20140302146A1 (en) 2011-07-08 2014-10-09 Rohto Pharmaceutical Co.,Ltd. Ophthalmic Aqueous Composition
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
KR101492447B1 (ko) 2013-05-20 2015-02-23 주식회사태준제약 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법
US10963928B2 (en) 2014-08-21 2021-03-30 Stubhub, Inc. Crowdsourcing seat quality in a venue
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
KR20170032808A (ko) * 2015-09-15 2017-03-23 주식회사 엘지생활건강 멘톨 또는 멘톨 유도체를 포함하는 용해성 미세바늘 패치
CN105726479B (zh) 2016-03-24 2018-06-22 北京茗泽中和药物研究有限公司 环孢素眼用乳剂
US11583496B2 (en) 2016-10-12 2023-02-21 PS Therapy Inc. Drug vehicle compositions and methods of use thereof
CA3039464C (en) * 2016-10-12 2026-02-17 Ps Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
KR102665630B1 (ko) 2017-12-07 2024-05-14 라이온 가부시키가이샤 수성 안과용 조성물 및 에멀션 입자의 미립화 방법
CN110090294A (zh) 2019-04-09 2019-08-06 嘉兴市爵拓科技有限公司 具有改善的干燥保护和保留的眼用组合物

Also Published As

Publication number Publication date
KR20210030215A (ko) 2021-03-17
JP2022548221A (ja) 2022-11-17
WO2021049825A1 (ko) 2021-03-18
KR102638866B1 (ko) 2024-02-21
KR102273481B1 (ko) 2021-07-06
US12576126B2 (en) 2026-03-17
US20240041974A1 (en) 2024-02-08
KR20210084389A (ko) 2021-07-07
EP4029493A1 (en) 2022-07-20
PH12022550500A1 (en) 2023-10-18
EP4029493A4 (en) 2023-10-04
CN114364372A (zh) 2022-04-15

Similar Documents

Publication Publication Date Title
JP5441058B2 (ja) 四級アンモニウム化合物を含む組成物
JP6603785B2 (ja) 水溶性高分子を含む水性液剤
CN101977630B (zh) 眼药组合物
JP2022511335A (ja) 人工涙液組成物、コンタクトレンズ組成物及び薬剤ビヒクル組成物、並びにこれらの使用の方法
CN104814924A (zh) 一种布佐林胺脂质体眼用制剂及其制备方法
CN103079595B (zh) 滴眼用水性组合物
US12576126B2 (en) Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof
EP4013443A1 (en) In-situ gel containing cyclosporine micelles as sustained ophthalmic drug delivery system
KR102365008B1 (ko) 디쿠아포솔을 포함하는 점안 조성물
CN113577024A (zh) 一种眼用组合物及其制备方法和应用
JPWO2018074421A1 (ja) 眼科用剤及び眼科用薬
DK3229780T3 (en) Ophthalmic composition for use in the treatment of dry eye syndrome
JP2002506808A (ja) グリコーゲン含有眼用溶液
CN104721136A (zh) 一种布佐林胺眼用纳米混悬剂及其制备方法
CN110022856B (zh) 用于降低眼压的眼用组合物
JP4263418B2 (ja) 熱ゲル化人工涙液
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
KR100938233B1 (ko) 프로스타글란딘계 점안용 조성물과 그의 제조 방법
CN112294761A (zh) 一种难溶性药物的眼用胶束制剂
CA2567418C (en) Viscous agent for ophthalmic use
WO2020138135A1 (ja) 眼科用組成物
US20240009124A1 (en) Ophthalmic Suspension Base having a Micro-fluidized Positively Charged Nanoparticle
WO2010120841A1 (en) Aqueous ophthalmic compositions containing anionic therapeutic agents
Mundada Update on Polymers for Ocular Drug Delivery
KR20130038512A (ko) 사이클로스포린 함유 안약 조성물 및 그 제조방법

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231